Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
Crossref DOI link: https://doi.org/10.1186/s12882-016-0256-0
Published Online: 2016-04-28
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nguyen, Hai V.
Bose, Saideep
Finkelstein, Eric
Funding for this research was provided by:
Sanofi-Aventis (Singapore)
